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Abstract
Many issues regarding the management of renal replacement therapy (RRT) in acute kidney injury (AKI) including
timing of initiation, selection of RRT modality, and optimal dosing remain to be resolved. Two major randomized
controlled trials, the Veterans Affairs/National Institutes of Health (VA/NIH) Acute Renal Failure Trial Network (ATN)
and the Randomized Evaluation of Normal versus Augmented Level (RENAL) studies, which were elaborately
designed to evaluate the benefit for delivering RRT of higher intensity in critically ill patients, were characterized by
their sophisticated design, large sample sizes, and comprehensive data collection. Although no beneficial effect of
higher intensity RRT was demonstrated by these studies, many ancillary studies conducted subanalyses which
provided additional findings on other important clinical questions that remained unsolved. This review aims to
overview the useful information obtained by the VA/NIH ATN and the RENAL studies to gain useful insights for
optimal RRT in AKI.
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Background
The incidence of acute kidney injury (AKI) in the inten-
sive care unit (ICU) is unacceptably high, affecting ap-
proximately two thirds of the patients [1, 2]. Among
those with severe AKI, 50–70 % eventually receive renal
replacement therapy (RRT) [3]. Furthermore, AKI in the
ICU is associated with higher mortality, particularly in
patients receiving RRT with 50–60 % mortality [3]. Even
after surviving hospitalization with AKI, dialysis depend-
ence rate in these patients following discharge is between
5 and 20 % [3, 4]. In addition to these poor outcomes,
many fundamental issues regarding the management of
RRT in AKI need to be resolved to improve its prognosis.
The Veterans Affairs/National Institutes of Health
(VA/NIH) Acute Renal Failure Trial Network (ATN) [5]
and the Randomized Evaluation of Normal versus
Augmented Level (RENAL) studies [6] were two major
randomized controlled trials (RCTs) that evaluated the
benefit of higher-intensity RRT. Although no beneficial
effect because of higher RRT intensity was demonstrated
by these studies, several subanalysis studies provided
useful information on the management of RRT in AKI
as these studies enrolled sufficient number of patients
and obtained comprehensive and detailed clinical data.
Review
Unanswered questions in RRT for treatment of AKI
The Kidney Disease: Improving Global Outcomes
(KDIGO) Clinical Practice Guideline for Acute Kidney
Injury [7] contains a list of the unanswered questions re-
garding RRT management for the treatment of AKI with
research recommendations in Section 5 (Table 1). In
addition to these issues, several topics including mortality
prediction, optimal drug prescription and nutritional sup-
port, and long-term outcomes, such as renal recovery and
quality of life, in dialysis-requiring AKI remain unresolved.
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Table 1 Topics of RRT in AKI described in the KDIGO guidelines
Timing of RRT in AKI
Criteria for stopping RRT in AKI
Anticoagulation
Vascular access for RRT in AKI
Dialyzer membranes for RRT in AKI
Modality of RRT for patients with AKI
Buffer solutions for RRT in patients with AKI
Dose of RRT in AKI
RRT renal replacement therapy, AKI acute kidney injury, KDIGO Kidney Disease:
Improving Global Outcome
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dress these questions, the subanalysis of large clinical trials
may provide useful information (Table 2).
Dose of RRT in AKI
Dose of RRT in AKI has been investigated by two major
RCTs, the VA/NIH ATN and the RENAL studies.Table 2 Subanalysis of the VA/NIH ATN and the RENAL studies
Topics Author (year) Ref Main result
Dose VA/NIH ATN Palevsky (2008) [5] No difference i
RENAL Bellomo (2009) [6] No difference i
RENAL Bellomo (2013) [8] No difference i
groups. The hig
in norepinephr
VA/NIH ATN Overberger (2007) [9] Intermittent he
in the USA. Mo
routinely assess
Timing RENAL Jun (2014) [16] Earlier commen
significantly ass
Risk prediction VA/NIH ATN Demirjian (2011) [20] 21 independen
outperformed
60-day mortalit
Drug RENAL Wang (2014) [23] The use of ACE
time-dependen
RENAL Roberts (2015) [25] CRRT dose did
distribution, or
Nutrition RENAL Bellomo (2014) [36] Mean DPI was
analysis, a lowe
RENAL Bellomo (2014) [32] Mean DCI durin
not associated
Renal recovery VA/NIH ATN Srisawat (2011) [41] For predicting
associated with
Quality of life VA/NIH ATN Johansen (2010) [43] Health utility w
did not affect s
VA/NIH ATN Joyce (2012) [44] HRQOL was an
adjusting for cl
RENAL Wang (2015) [45] Survivors of sev
of HRQOL com
reduced renal
ACE-I angiotensin-converting enzyme inhibitor, AKI acute renal failure, ATN Acute Re
caloric intake, DPI daily protein intake, HRQOL Health-related quality of life, MAP me
Normal versus Augmented Level, RIFLE-I Risk, Injury, Failure, Loss, End-stage kidneyKDIGO guideline recommends delivering a Kt/V of 3.9
per week for intermittent RRT or an effluent volume of
20–25 ml/kg/h for continuous renal replacement therapy
(CRRT) in AKI based on the findings of these two trials.
The VA/NIH ATN study was a multicenter, prospective,
randomized, parallel group trial of two strategies for RRT
in critically ill patients with AKI conducted at 27 VA
and university-affiliated medical centers; 1124 critic-
ally ill patients with AKI and failure of at least one
non-renal organ or sepsis were randomly assigned to
receive either intensive or less intensive RRT. The
primary endpoint was death from any cause by day
60. In the group receiving the intensive/less intensive
therapy strategy, intermittent hemodialysis (IHD) and
sustained low-efficiency dialysis (SLED) were provided
three to six times per week, and continuous hemodia-
filtration was prescribed to provide a total effluent
flow rate of 35 or 20 ml/kg/h. The results showed no
significant differences in the rate of death from any cause
by day 60, the duration of RRT, the rate of recovery ofn 60-day mortality between the intensive and less intensive groups
n 90-day mortality between the higher and lower intensity groups
n base excess correction between the higher and lower intensity
her intensity group had a greater increase in MAP and a decrease
ine dose.
modialysis and CRRT were the most commonly used RRT modalities
st practitioners neither dosed CRRT based on patient weight nor
ed the delivered dosage of hemodialysis.
cement of continuous RRT relative to RIFLE-I AKI onset was not
ociated with improved mortality.
t predictors of 60-day mortality were identified. The new risk model
existing generic and disease-specific scoring systems in predicting
y.
-I during the study was not common and, after adjustment for
t covariates, was not significantly associated with reductions in mortality.
not influence overall (systemic) antibiotic clearance, volume of
half-life. The proportion of systemic clearance due to CRRT varied widely.
markedly below current recommendations. On multivariate
r DPI was not associated with increased 90-day mortality.
g treatment in ICU was low. On multivariable analysis, DCI was
with a significant difference in 90-day mortality.
renal recovery, decreasing urine biomarkers in the first 14 days was
greater odds of renal recovery.
as low in this cohort of patients after AKI, and intensity of dialysis
ubsequent health utility.
independent predictor of mortality among survivors of AKI after
inical risk variables.
ere AKI in the study had lower physical and mental components
pared with the general population, even after adjustment for
function.
nal Failure Trial, CRRT continuous renal replacement therapy, DCI delivery of
an arterial pressure, ICU intensive care unit, RENAL Randomized Evaluation of
disease (injury), VA/NIH The Veterans Affairs/National Institutes of Health
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two groups [5].
The RENAL study was a prospective, randomized, par-
allel group trial designed to assess CRRT at two levels of
intensity in critically ill patients with AKI. Eligible 1508
patients were randomly assigned to two groups based on
delivery of CRRT with an effluent flow of 40 ml/kg/h
(higher intensity) or 25 ml/kg/h (lower intensity). At
90 days after randomization, 322 deaths occurred in the
higher intensity group, whereas 332 deaths were re-
corded in the lower intensity group; the difference be-
tween the two groups was not statistically significant [6].
Although these two RCTs could not prove the benefit of
intensive RRT in terms of mortality and renal recovery,
other non-primary outcomes including the need for vaso-
pressor drugs, time on mechanical ventilation, or length
of ICU and hospital stay were also evaluated. Bellomo and
colleagues conducted a nested cohort study of 115 pa-
tients from two tertiary ICUs within the RENAL study to
compare key aspects of acidosis, mean arterial pressure
(MAP), and vasopressor therapy in patients treated with
two different CRRT doses. They showed that lower and
higher intensity CRRT had similar acid-base effects in pa-
tients with acidosis. However, higher intensity CRRT was
associated with greater improvements in MAP and vaso-
pressor requirements [8]. A potential mechanism could be
a more efficient removal of biologic mediators responsible
for hypotension and/or vasodilatation by higher intensity
CRRT, which should be validated by future studies.
Most trials studying CRRT dose used the amount of
effluent volume normalized by the patient weight. Over-
berger and colleagues pointed out that only 17.9 % of
practitioners reported dosing CRRT according to patient
weight and that 78.9 % of practitioners did not routinely
assess the delivered hemodialysis dose based on the sur-
vey results from study sites of the VA/NIH ATN [9].
Due to daily changes in patient weight in the ICU, CRRT
dose could not guaranteed to be equally prescribed
throughout the study period when the body weight be-
fore the onset of acute illness (VA/NIH ATN study) or
at the time of randomization (RENAL study) was used
for prescription. Differences between the prescribed and
delivered CRRT doses may have had some impact on
the outcomes of both clinical trials. Claure-Del Granado
and colleagues reported that prescribed clearance overesti-
mated the actual delivered clearance by 23.8 % in 52 AKI
patients treated by continuous hemodiafiltration [10].
Future trials need to more clearly determine the dosing
parameters and recognize the frequent discrepancy be-
tween the prescribed and delivered doses of RRT.
Timing of RRT in AKI
The time to start RRT is one of the top research priorities
and a fundamental clinical question facing nephrologistsand intensivists in most cases of severe AKI [11]. While
there is still no agreement on the timing of RRT initiation,
it is widely accepted that patients with severe hyperkale-
mia, severe acidosis, diuretic-resistant pulmonary edema,
and uremic complications should be dialyzed immediately.
Clinicians tend to delay RRT when they suspect that
patients may recover on their own and due to concern
of risks associated with RRT, including hypotension,
arrhythmia, membrane bio-incompatibility, and complica-
tions from vascular access and anticoagulant administra-
tion. The KDIGO guideline recommended determining
reproducible criteria to inform decision to start RRT in
AKI patients by future research [7].
There are several observational study results showing
positive results with early RRT commencement. One
prospective, multicenter, observational cohort study ana-
lyzed dialysis initiation in 243 AKI patients. Initiation of
RRT at higher blood urea nitrogen (BUN, >76 mg/dl)
was associated with an increased risk of death (relative
risk (RR), 1.85; 95 % confidence interval (CI), 1.16–2.96)
after adjustment for clinical background and severity of
illness [12]. In another prospective, multicenter observa-
tional study with a bigger sample size of 1238 ICU
patients with severe AKI, investigators assessed the rela-
tionship between patient outcomes and the time to start
RRT relative to ICU admission. After adjustment, late
RRT (defined by initiation 5 days after ICU admission)
was associated with an increase in the odds of death
(odds ratio (OR), 2.20; 95 % CI, 1.44–3.37) [13].
A meta-analysis which included data from four RCTs,
1 quasi-RCT, and 18 observational studies suggested a
potential advantage of early CRRT commencement,
reporting a non-significant point estimate of 36 % mor-
tality risk reduction (RR, 0.61; 95 % CI, 0.40–1.05) from
RCT data [14]. The RCT with the highest quality score
in this meta-analysis randomized 106 critically ill pa-
tients with AKI to early (n = 70) vs. late CRRT initiation
(n = 36). The early initiation group started RRT within
12 h of oliguria (30 ml/h for 6 h, not responding to di-
uretics or hemodynamic optimization) or creatinine clear-
ance of <20 ml/min. The late-initiation group started RRT
when classic indications were met. The study did not find
differences in ICU or hospital mortality or in renal recov-
ery among survivors; however, their sample size might be
too small to allow for definitive conclusions [15].
Jun and colleagues conducted a nested observational co-
hort study using data from the RENAL study [16]. Earlier
commencement of CRRT relative to Risk, Injury, Failure,
Loss, End-stage kidney disease-injury (RIFLE-I) AKI onset
was not significantly associated with improved mortality;
however, non-significant graded increases in the risk of
death with progressively delayed CRRT were observed.
The study also found a significant association of mortality
with BUN levels at the commencement of RRT. The
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garding the standard criteria used to evaluate early versus
late RRT commencement. The ideal criteria might not be
BUN, time from ICU admission, or AKI onset used in pre-
vious observational studies investigating CRRT efficacy.
Additional future studies with larger sample sizes and
randomization using elaborately designed criteria, poten-
tially with new biomarker levels or systemic severity
scores, will address these potential variables.
Risk prediction in AKI
As widely recognized, the short-term prognosis of AKI
patients in the ICU is very poor. Risk assessment and
mortality prediction are important for developing new
therapeutic interventions against AKI. The application
of systemic severity scores for AKI patients has been
problematic due to poor discrimination and suboptimal
calibration [17, 18]. Chertow and colleagues developed
models with the data from the Program to Improve Care
in Acute Renal Disease (PICARD) cohort, a registry of
critically ill patients with acute renal failure in the ICUs
of five academic medical centers in the United States
over a 31-month period (n = 618) [18]. They demon-
strated marginally superior performance characteristics
compared with other prediction models of Sepsis-related
Organ Failure Assessment (SOFA) or Cleveland Clinic
Foundation (CCF) scores, which reportedly could predict
the survival of patients with renal failure [19]. The SOFA
score was the best performer among all generic severity
scores, whereas the CCF score was the best performer
among all disease-specific severity scores [18].
Demirjian and colleagues analyzed the data from 1122
subjects enrolled in the VA/NIH ATN study to develop
an AKI-specific predictive model for a 60-day mortality.
The logistic regression model exhibited good discrimin-
ation, with an area under the receiver operating charac-
teristics curve (AUC-ROC) of 0.85 (95 % CI, 0.83–0.88),
and a derived integer risk score yielded an AUC-ROC of
0.80 (95 % CI, 0.77–0.83) [20]. The model can be used
for risk evaluation and to potentially stratify prospective
subjects in clinical AKI trials after further validation of
the model in other cohorts.
Optimal drug prescription in AKI
Although the renoprotective effect of angiotensin-
converting enzyme inhibitors (ACE-I) or angiotensin re-
ceptor blockers (ARB) in chronic kidney disease (CKD)
is well recognized for reducing proteinuria and slowing
progression of renal dysfunction, the role of ACE-I or
ARB in AKI remains uncertain. Theoretically, these
drugs reduce intraglomerular pressure and glomerular
filtration rate (GFR) and may worsen AKI severity by
increasing serum creatinine level. In the setting of
cardiac surgery, Benedetto and colleagues showed thatpreoperative ACE-I use until the day of on-pump coron-
ary artery bypass grafting reduced the incidence of postop-
erative AKI [21]. However, Arora and colleagues reported
preoperative use of ACE-I or ARB were independently as-
sociated with a higher risk of postoperative AKI [22].
Wang and colleagues examined the effect of ACE-I
prescription on clinical outcomes in AKI by analyzing
the RENAL study data. The use of ACE-I during the
study was not common (9.7 %) and was not signifi-
cantly associated with a reduction in mortality after
adjusting for time-dependent covariates [23]. Further
evaluation is required to optimize renin-angiotensin
system blockade treatment in AKI.
Another important consideration in the setting of AKI
requiring RRT is antibiotic use, as dose adjustment
based on renal dysfunction and dialysis intensity is re-
quired. Fundamental aspects of pharmacokinetics in-
cluding clearance (CL) and volume of distribution (Vd)
are drastically changed in critically ill patients with AKI
due to loss of renal clearance, volume expansion, and in-
terventions such as vasopressors and RRT. As CRRT-
associated variables, effluent flow (dialysate flow, ultrafil-
tration rate), membrane fouling, and filter clotting can
influence extracorporeal CL during CRRT. So far, data
on antibiotic pharmacokinetics during CRRT are limited
[24]. Roberts and colleagues studied 24 patients in the
RENAL study to assess the effect of CRRT on extracor-
poreal and systemic antibiotic CL and Vd. They showed
that there was great variability in multiple antibiotic
pharmacokinetics, with greater variation observed in
systemic CL than in Vd. These changes were not affected
significantly by CRRT dose, suggesting the need for
individual therapeutic drug monitoring regardless of
CRRT dose [25].
Nutritional support in AKI
Achieving an adequate daily calorie intake (DCI) is con-
sidered beneficial in critically ill patients, especially in
those complicated with AKI [26]. In an RCT that com-
pared energy provision of 30 and 40 kcal/kg/day for AKI
patients, the higher energy prescription did not induce a
more positive nitrogen balance but was associated with a
higher incidence of hyperglycemia and hypertriglyc-
eridemia and a more positive fluid balance [27]. The
KDIGO and the European Society for Clinical Nutrition
and Metabolism (ESPEN) recommend achieving a total
energy intake of 20–30 kcal/kg/day in patients with any
stage of AKI [28]. Conversely, caloric restriction may be
beneficial for critically ill patients with respiratory failure
because of low CO2 production. However, two RCTs
involving patients with acute lung injury or acute re-
spiratory failure evaluated minimal or trophic enteral
feeding (15–25 % of estimated caloric requirements)
with no protein supplementation for up to 6 days and
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with standard enteral feeding [29, 30]. A systematic review
that evaluated eight RCTs concluded that there was insuf-
ficient evidence to support the effectiveness of nutritional
support for AKI [31]. Especially in severe AKI requiring
CRRT, there is very limited data on current practices or
on the association of energy intake with the outcomes.
Bellomo and colleagues described calorie administration
in patients enrolled in the RENAL study and evaluated the
association of DCI with clinical outcomes. In the RENAL
study, mean DCI appeared to be low; the mean DCI dur-
ing treatment in the ICU was low at only 10.9 ± 9 kcal/kg/
day for non-survivors and 11 ± 9 kcal/kg/day for survivors.
Within the limits of such low caloric intake, greater DCI
was not associated with improved clinical outcomes [32].
Higher level evidence is needed to better define the opti-
mal DCI target in AKI patients.
Another issue regarding nutrition in AKI patients is the
amount of protein intake. Delivering an adequate daily
protein intake (DPI) is considered beneficial in critically ill
patients in general and in patients with AKI specifically.
The American Society for Parenteral and Enteral Nutri-
tion (ASPEN) Guidelines recommend administering at
least 1.0 g/kg/day to patients with AKI requiring RRT with
a maximum of 1.7–2.5 g/kg/day [33]. Two prospective tri-
als suggested a protein intake of 2.5 g/kg/day was neces-
sary to achieve positive nitrogen balance in patients with
AKI requiring RRT [34, 35]. However, no outcome data
are currently available concerning the clinical efficacy and
safety of such high protein intake. In addition, most studies
on protein intake in AKI conducted so far were small,
single-center trials and evaluated only the nitrogen balance.
Bellomo and colleagues conducted a secondary ana-
lysis of the RENAL study findings focusing on the rela-
tionship between DPI and clinical outcomes. Patients in
the RENAL study received a low DPI (0.5 g/kg/day),
markedly below current recommendations. However, a
low DPI was not independently associated with a decreased
risk of death at 90 days or an increase in mechanical venti-
lation, RRT, ICU, or hospital-free days [36]. Thus, as with
DCI, data is not clear on the optimal DPI target in AKI pa-
tients. Further RCTs are needed to determine the optimal
DCI and DPI targets according to the stage of AKI and
RRT requirement.
Long-term outcomes in AKI: renal recovery and quality of life
The long-term outcomes and renal recovery of AKI are
important issues; however, they are not as well-
characterized as short-term prognoses. Despite signifi-
cant progress in the epidemiology of AKI, forecasting
long-term outcomes and renal recovery in each AKI pa-
tient continues to be a challenge. Three RCTs comparing
the efficacy of CRRT versus intermittent hemodialysis
found that Acute Physiology, Age, Chronic HealthEvaluation (APACHE) III score of >100 [37], low urine
output, decrease in MAP after initiation of dialysis [38],
and pre-existing renal impairment [39] were associated
with poor renal recovery. Uchino and colleagues re-
ported that baseline creatinine and urine output values
at the time of RRT discontinuation were the strongest
predictors of renal recovery based on the post hoc ana-
lysis of the Beginning and Ending Supportive Therapy
for the Kidney (BEST Kidney) study [40], a large inter-
national epidemiological survey of acute renal failure in
ICU patients [3].
Srisawat and colleagues conducted an ancillary study
to the VA/NIH ATN study to determine whether bio-
markers could aid in clinical risk prediction for recovery
after AKI. They showed that decreased urinary neutro-
phil gelatinase-associated lipocalin (uNGAL) and urinary
hepatocyte growth factor (uHGF) within the first 14 days
after starting RRT were associated with greater odds of
renal recovery. The best predictive model combined
relative changes in biomarkers with clinical variables and
had an AUC-ROC of 0.94 [41]. In addition to conventional
clinical parameters, more accurate methods to predict
renal recovery including the development and utilization
of new AKI biomarkers are warranted to minimize the
clinical uncertainty and complexity of medical decision-
making during AKI treatment.
Health-related quality of life (HRQOL) after AKI is an
area of great importance to patients. Noble and col-
leagues showed that quality of life (QOL) scores assessed
by the Short Form-36 were significantly lower for overall
physical health as well as for seven of the eight domains
in AKI survivors than in general population [42]. Johansen
and colleagues examined whether study treatment as-
signment (intensity of dialysis) and ongoing dialysis de-
pendence at 60 days were potential determinants of
HRQOL in the VA/NIH ATN study cohort. Health util-
ity index score was low (0.40 ± 0.37) in this AKI sur-
vivor cohort, and the intensity of dialysis did not affect
subsequent health utility whereas the length of hospital
and ICU stay did [43]. Using the VA/NIH ATN study
cohort, Joyce and colleagues conducted another study
revealing that HRQOL measured by Health Utilities
Index Mark 3 (HUI3) was an independent predictor of
mortality among survivors of AKI after adjusting for
clinical risk variables [44].
Wang and colleagues conducted an extension study
within the RENAL study cohort by following up AKI sur-
vivors to evaluate the impact of AKI on long-term
HRQOL (3.5 years after the RENAL study randomization).
Unadjusted analyses showed that AKI patients had lower
physical component scores (PCS; mean score, 40.0 vs.
49.8, P < 0.0001) and lower mental component scores
(MCS; mean score, 49.8 vs. 53.9, P < 0.0001) than the gen-
eral population. Advanced age, reduced renal function,
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PCS values [45]. The HRQOL may provide additional in-
formation to identify patients at high risk of mortality after
surviving AKI.
Perspectives
Recent clinical guidelines consist of a list of clinical ques-
tions and answers. Strong evidence supported by numer-
ous RCTs and high-quality meta-analysis studies are
necessary to confirm the recommendations in the guide-
lines. However, economic, human resources, and ethical
limitations hamper ideal RCTs designed to answer all clin-
ical questions. Alternatively, clinically useful information
can be retrieved from additional subanalyses or ancillary
studies that use data from existing RCTs. Although the
strength of evidence derived from the subanalysis studies
described in this review was not sufficient compared with
the two original RCTs (VA/NIH ATN and RENAL), the
reported information by these subanalyses provide mean-
ingful insights that can be applied to the clinical practice.
It should be noted that the two RCTs have comprehensive
and well-organized databases with large sample sizes.
Conclusions
This review summarizes additional findings related to RRT
in AKI patients derived from the two landmark RCTs, the
VA/NIH ATN and the RENAL studies. Although these
two RCTs demonstrated no beneficial effect with
higher intensity RRT, additional useful information from
subanalyses of these RCTs can be obtained.
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I: Risk, Injury, Failure, Loss, End-stage kidney disease (injury); RR: relative risk;
RRT: renal replacement therapy; SLED: sustained low efficiency dialysis;
uHGF: urinary hepatocyte growth factor; uNGAL: urinary neutrophil
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